Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma
F Maibach, H Sadozai, SM Seyed Jafari… - Frontiers in …, 2020 - frontiersin.org
Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB)
antibodies, have demonstrated the capacity of the immune system to fight cancer in a …
antibodies, have demonstrated the capacity of the immune system to fight cancer in a …
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Overexpression of the B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a
major immune evasion mechanism in some patients with cancer, and antibody blockade of …
major immune evasion mechanism in some patients with cancer, and antibody blockade of …
[HTML][HTML] Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Background Treatment options for previously treated metastatic triple-negative breast cancer
(mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated …
(mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated …
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …
shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this …
[HTML][HTML] Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
Background Standard first-line treatment of metastatic triple-negative breast cancer
(mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are …
(mTNBC) is chemotherapy. However, outcomes are poor, and new treatment options are …
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …
cancer, there remains a need for effective treatments for progressive disease. We assessed …
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …
strategy. Several lines of evidence support the study of immunotherapy in triple-negative …
Ferroptosis: a double-edged sword mediating immune tolerance of cancer
Q Dang, Z Sun, Y Wang, L Wang, Z Liu, X Han - Cell death & disease, 2022 - nature.com
The term ferroptosis was put forward in 2012 and has been researched exponentially over
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
the past few years. Ferroptosis is an unconventional pattern of iron-dependent programmed …
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
SE Stanton, ML Disis - Journal for immunotherapy of cancer, 2016 - Springer
Tumor infiltrating lymphocytes (TIL) play an essential role in mediating response to
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …
chemotherapy and improving clinical outcomes in all subtypes of breast cancer. Triple …